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Shao-Liang Han, Hong-Zhong Zhou, Jun Cheng, Sheng-Hong Lan, Pei-Chen Zhang, Zhe-Jing Chen and 
Qi-Qiang Zeng, Department of General Surgery, The First Affiliated Hospital of Wenzhou Medical College, 
Wenzhou, China.
Liver malignancy is known to be associated with hepatolithiasis. The present report summarises the
results and our experience for management of 23 patients with intrahepatic hepatolithiasis associated
cholangiocarcinoma (IHHCC). The correct diagnosis rates of US (ultrasonography), CT (computed
tomography), and MRCP (magnetic resonance cholangiopancreatography) were 82.6% (19/23), 95.7%
(22/23), and 91.7% (11/12), respectively. Carbohydrate antigen 19-9 (CA 19-9) was helpful in the diagnosis
of IHHCC. All 23 patients with IHHCC underwent laparotomy. The surgical procedure consisted hepa-
tectomy with a bile duct exploration in 16 patients (69.6%), a hepatectomy and drainage procedure such as
sphincteroplasty and choledo-jejunostomy in three patients (13.0%), a bile duct exploration with biopsy
in two patients (8.7%), and simple laparotomy and biopsy in two patients (8.7%). All the IHHCC patients
who underwent a palliative procedure or laparotomy died within 1 year, and the overall cumulative sur-
vival rates at 1, 3, and 5 years were 43.8% (10/23), 13.0% (3/23), and 4.3% (1/23), respectively, and those
patients who underwent curative resection were 88.9% (8/9), 33.3% (3/9), and 11.1% (1/9), respectively,
which significantly longer than those (20.0%, 2/10; 0.0%, 0/10; and 0.0%, 0/10) patients who underwent
palliative resection, respectively (p<0.05). A suspicion of malignancy is necessary when managing patients
with long-term hepatolithiasis. Hepatic resection with postoperative treatment is the treatment of choice
for cholangiocarcinoma when it is resectable. [Asian J Surg 2009;32(1):1–6]
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Introduction
Intrahepatic cholangiocarcinoma (IHCC) is a malignant
tumour occurring in the liver or arising from the second
or more distal branches of the intrahepatic bile ducts.1
The incidence of IHCC exhibits wide geographical varia-
tion, and generally accounts for between 5% and 30% of
primary liver cancers.1 According to the Japan Liver
Cancer Society, histologically proven IHCC represented
3.58% of all primary liver cancers.2 Early detection of
cholangiocarcinoma has been difficult and the overall
survival after resection remains poor compared with that
of hepatocellular carcinoma (HCC). The clinical features
and the population at high risk of IHCC are not well clar-
ified, in order to the well-defined high-risk group in HCC.
Although no specific aetiological factor has been identi-
fied for IHCC, various well-recognised predisposing con-
ditions involving chronic inflammation of the bile ducts
exist.3–9 These conditions include hepatolithiasis, primary
sclerosing cholangitis,5,6 choledochal cysts,7,8 and Caroli’s
disease.9 Clinically, IHCC remains challenging because 
it is difficult to diagnose in its early stages, and patients
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typically do not present until the disease is quite advanced
because of the vague symptoms. Curative resection with
clear margins and without vascular or lymphatic invasion
is infrequent and recurrence is common. Three- to five-
year survival rates even with resection remain dismal.10–13
Hepatolithiasis is a common disease in China and 5%
to 10% of hepatolithiasis is known to be associated with
cholangiocarcinoma.14,15 However, it is difficult to detect
early cholangiocarcinoma that occurs as a complication
of hepatolithiasis. The clinicopathologic features of hepa-
tocellular carcinoma patients have been well described in
literature.2,16 On the other hand the biological behaviour
of primary hepatic cholangiocarcinoma, especially intra-
hepatic hepatolithiasis associated cholangiocarcinoma
(IHHCC) has not been fully clarified. To investigate the
clinicopathologic features of IHHCC, we retrospectively
analysed the clinical and pathologic data of resected
IHHCC at our hospital.
Patients and methods
From July 1982 to January 2006, 23 consecutive patients
with histologically proven IHHCC, underwent surgical
treatment at the Department of General Surgery, the First
Hospital of Wenzhou Medical College, Wenzhou, China.
IHCC was defined as carcinoma arising from second
order or more distal branches of the intrahepatic ducts.
Meanwhile, a curative resection was defined as negative
resection margin observed during histopathological
examination, that is, R0 resection.
General data
The general data of patients with IHHCC is presented in
Table 1. IHHCC occurred predominantly in men in this
study. There were 14 males and 9 females with a male to
female ratio of 1.56:1; the mean age was 57.6 years with
patients ages ranging from 40 to 74 years. The mean dura-
tion from the onset of the disease to diagnosis was 8.3
months, ranging from 1 month to 38 months.
Clinical presentation
The clinical manifestations in patients with IHHCC were
not specific. We found that the most common symptom
on admission was patients who presented with right
upper abdominal pain and tenderness 73.9% (17/23). This
was, followed by 56.5% (13/23) of patients with fever and
chills, 47.8% (11/23) of patients with a loss of appetite,
65.2% (15/23) of patients with liver enlargement, 34.8%
(8/23) of patients with jaundice and 8.7% (2/23) of pa-
tients with ascites. Twenty-one patients had a history of
stone disease, four patients had a history of hepatitis B,
three patients were positive with hepatitis B surface anti-
gen (HBsAg) and slightly elevated alpha-fetoprotein
(AFP) (normal limits of 0.0–20.0 ug/L) was present in two
patients. The mean history of hepatolithiasis was 7.2
years, ranging from 5 years to 36 years.
Follow-up study
Follow-up evaluation included clinical physical examina-
tions and blood chemistry tests at each visit. Additionally,
serum carbohydrate antigen (CA19-9) (a glycoprotein
tumour marker, with normal limits of 0.0–37.0 U/mL)
and carcinoembryonic antigen (CEA; normal limits of
0.0–5.0 ug/L) were both measured, and the remnant liver
was examined with US every 3 months. When US detected
a new lesion or elevated CA 19-9 or when CEA were noted,
abdominal CT or MRCP was performed for confirmation.
Moreover, when patients complained of bone pain, bone
scans were performed to detect possible metastasis. If any
of the above procedures indicated recurrence, the patient
was readmitted for more compressive assessment, including
angiographic evaluation or magnetic resonance imaging
(MRI). Treatment for tumour recurrence include surgery,
systemic chemotherapy, external beam radiotherapy,
intraluminal radiotherapy, interventional radiological
therapy, and conservative treatment.
Statistical analysis
SPSS for Windows statistics software (SPSS version 13.0,
Chicago, IL, USA) was used for the statistical analysis. The
cumulative survival rates were calculated with the Kaplan-
Meier method and a value of p < 0.05 was considered 
statistically significant.
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Table 1. Clinical presentation of IHHCC patients
Finding Number of patients (%)
Right upper abdominal pain 17 (73.9)
Liver enlargement 15 (65.2)
Fever and chill 13 (56.5)
Loss of appetite 11 (47.8)
Jaundice 8 (34.8)
Ascites 2 (8.7)
IHHCC = intrahepatic hepatolithiasis associated cholangiocarcinoma.
Results
Laboratory and imagine examination
Laboratory tests were conducted the day before surgery.
Serum CA 19-9 was elevated in 18 patients (78.3%), and
CEA was slightly elevated only in two patients (8.7%). The
tumours were preoperatively evaluated by abdominal US,
CT, and MRCP. All patients with IHHCC were scanned by
US and the correct diagnosis obtained was 82.6% (19/23).
The diagnosis rate of the CT scans was 95.7% (22/23), 
and the diagnosis rate of MRCP was 91.7% (11/12, only
the latest twelve patients received the MRI scan).
The tumour stage was defined according to the patho-
logical tumour node metastasis (pTNM system) classifi-
cation proposed by the UICC.17 Stages II and I were
assigned as early-stage and Stages III and IV as advanced-
stage disease (Table 2). There was no early stage disease in
this study; all diseases were at an advanced stage, compris-
ing of 17 patients with Stage III disease and six patients
with Stage IV. Adjuvant chemotherapy was unsystemati-
cally performed with a 5-flurouracil-based regimen due
to either a positive section margin or local recurrence.
Operative and histopathological findings
All tumours were near or at the sites of the stone located
including tumours located at the left lobe in 16 patients,
the right lobe in four patients, the bilateral lobes in two
patients, and caudate lobe in one patient. The tumour
presented as a massive type in 16 patients, nodular type
in five patients and a diffused type through the whole liver
in two patients. The mean size of IHHCC was 6.7 cm in
diameter, varying from 4 cm to 12 cm. The tumour did in-
volve the capsule in 15 patients, but did not in 8 patients.
The cut surface showed marked fibrosis around the
dilated bile duct, with atrophy of the liver parenchyma.
Microscopic examination of the resected liver specimen
revealed no evidence of malignancy. The epithelium of the
dilated bile duct distant from the tumour often showed
papillomatous and adenomatous hyperplasia with mod-
erate atypia. There was also proliferation of many glands.
A chronic inflammatory infiltrate was present in the
periductal fibrous stroma.
The bile duct wall was markedly thickened due to the
presence of cholangitis. Unilobular bile duct obstruction
usually results in atrophy of the affected hepatic lobe 
followed by hypertrophy of the unaffected lobe, forming
a so-called phenomenon known as the atrophy-hypertrophy
complex.18 Additionally, atrophy and fibrosis of the lobe,
abscess formation or a cholangitic appearance in the sur-
rounding liver parenchyma, and recurrent or retained
stones that had not be removed by other methods are suit-
able for hepatic resection. Bacteriology of the choledochal
bile taken during the operation revealed Escherichia coli
and Klebsiella. Chemical analysis of the intrahepatic stones
showed they were composed predominantly of bilirubin.
Operative procedure
All 23 patients with IHHCC underwent laparotomy. The
surgical procedure included irregular hepatectomy with
bile duct exploration in 16 patients (69.6%), hepatectomy
and drainage procedure (sphincteroplasty and choledoje-
junostomy) in three patients (13.0%), bile duct exploration
with biopsy in two patients (8.7%), and simple laparotomy
and biopsy in two patients (8.7%). The only postoperative
complications were incisional infections in three patients,
but there were no operative deaths in this group.
Survival
All the IHHCC patients undergoing surgical treatment
received regular postoperative follow-up until death or
the study deadline. No patients failed to follow-up. All the
IHHCC patients who underwent palliative procedure or
laparotomy died within 1 year. Among the 19 patients
with IHHCC, nine patients had a curative resection (cura-
tive resectability rate; 39.1%), 10 patients had a palliative
resection and four had a laparotomy and biopsy. Only one
patient who had a so-called small liver cancer (< 3 cm in
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Table 2. TNM pathologic classification of intrahepatic cholan-
giocellular carcinoma
Stage Tumour Node Metastasis
I T1 N0 M0
II T2 N0 M0
IIIA T3 N0 M0
IIIB T4 N0 M0
IIIC Any T N1 M0
IV Any T Any N M1
T1 = solitary tumour without vascular invasion; T2 = solitary tumour
with vascular invasion or multiple tumours, none >5 cm; T3 = multiple
tumours > 5 cm or tumour involving a major branch of the portal or
hepatic vein(s); T4 = tumours with direct invasion of adjacent organs
other than gallbladder or with perforation of visceral peritoneum;
N0 = no regional lymph node metastasis; N1 = regional lymph node
metastasis; M0 = no distant metastasis; M1 = distant metastasis.
diameter) survived than 5 years in this group. The overall
cumulative survival rates at 1, 3, and 5 years were 43.8%
(10/23), 13.0% (3/23), and 4.3% (1/23), respectively. For
those patients who received a curative resection the sur-
vival rates were 88.9% (8/9), 33.3% (3/9), and 11.1% (1/9),
at the same intervals respectively, which was significantly
longer than the patients who underwent palliative resec-
tion (20.0%, 2/10; 0.0%, 0/10; and 0.0%, 0/10), respectively
(p < 0.05) (Figure). Moreover, the disease-free survival
rates at 1, 3, and 5 years were 30.4% (7/23), 8.7% (2/23),
and 4.3% (1/23) respectively.
Discussion
Hepatolithiasis is more frequently seen in East Asian
countries than in Western countries, and it is well known
to represent a high-risk state for IHCC.19,20 IHCC is 
an aggressive tumour that shows a dismal outcome even
after resection.21 Cancer results from multistep carcino-
genesis; however, the precise molecular mechanism involved
in the genetic alteration in cancer remains unknown. The
accumulation of alterations in cancer-related genes leads
to disruptions in cell-cycle regulation and also to contin-
uous cell proliferation.
Chen et al14 reported that 5–6.5% of patients with
hepatolithiasis were associated with IHCC. Conversely,
they reported that 66% of patients with IHCC had con-
comitant hepatolithiasis. The pathologenetic relation-
ship between hepatolithiasis and IHCC is not well
established. Most authors have suggested that repeated
chronic infection and the bile stasis of hepatolithiasis can
lead to the development of mucosal adenomatous epithe-
lial hyperplasia and bile duct carcinoma.3–10 They have
also found that hepatolithiasis does not provide the sole
carcinogenic stimulus leading to malignancy. Bile duct
carcinoma arising in association with hepatolithiasis is
probably the cumulative result of several etiologic agents,
which may include nutritional, genetic, environmental,
and immunologic factors.21–24 Kim et al23 reported the ex-
pression of epidermal growth factor receptor (EGFR) was
increased in hepatolithiasis group (79%, 11/14) compared
with the cholangiocarcinoma group (25%, 5/20) (p<0.05),
and the expression of erbB2 (erythroblastic leukaemia
viral oncogene homolog 2) was detected only in cholan-
giocarcinoma (25%, 5/20).
Clinical presentation and diagnosis of IHHCC
Patients with IHHCC present with non-specific symp-
toms including abdominal pain, diminished appetite,
weight loss, malaise and night sweats, and incidental
abdominal mass which may be detected during either a
physical examination or imaging study.21,25,26 The clinical
manifestations of patients with IHHCC in this study,
were right upper abdominal pain, fever and chill, loss of
appetite, liver enlargement, jaundice and ascites.
Laboratory tests usually show increased tumour mark-
ers, such as CA 19-9, may be increased sometimes. Several
investigators have reported that CA 19-9 and CEA deter-
minations are useful for diagnosing peripheral cholangio-
carcinoma in primary sclerosing cholangitis.27 These
investigators also demonstrated that serum CA 19-9 values
are related to tumour burden, and suggested that values
were elevated in patients with PCC related to the unre-
sectable disease.27 A previous Japanese study has also
demonstrated that elevated serum tumour markers,
including CEA and CA 19-9, were a predictor of a dismal
prognosis.28 Although the reason for this is unclear, our
study also demonstrated that elevated CEA and CA 19-9
were predictors of dismal prognosis in univariate log-rank
analysis. Our results demonstrated that serum CA 19-9
was elevated in 78.3% patients, and CEA was slightly ele-
vated only in two patients (8.7%), differing from the reports
in the literature.27–29
Kawarada Y et al reported that serum CA 19-9 was ele-
vated in 42.7% of patients and CEA in 60.0% patients, both
of whom suffered from pancreatico-biliary system carci-
noma.29 In addition, Ohtsuka et al reported that serum
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Figure. Comparison between the overall cumulative survival
rates of patients who received curative and palliative resection.
CA 19-9 concentration was not only helpful in differenti-
ation diagnosis, but also a determining factor influenc-
ing survival.30 In our study, 25.5% patients had elevated
serum AFP, 6.4% patients had elevated serum CEA, and
75.0% patients (35/47) with IHHCC had elevated serum CA
19-9. These results indicated that a combination measure-
ment of AFP, a representative tumour marker for HCC,
and CA 19-9, a specific tumour marker for pancreatico-
biliary system carcinoma, was helpful in the differentia-
tion diagnosis of peripheral intrahepatic carcinoma.
The diagnosis rates of IHHCC by ultrasonography, CT
scan and selective angiography were 94%, 94%, and 83% in
available literature.4,31 However, it is difficult to differen-
tiate it from HCC, metastatic tumour and liver abscess.
Our data indicated that the diagnosis rate of ultrasonog-
raphy was 82.6% (19/23) the rate obtained by CT scan was
95.7% (22/23) and by MRCP was 91.7% (11/12). IHHCC
had no characteristic sonographic features, and it demon-
strated on ultrasonography as having low or isodensity,
irregular margins and it lacked vessel images and its fea-
tures varied greatly. Colour Doppler flow imaging usually
revealed a shortage of arterial blood flow. The typical fea-
tures of CT were as follows: (1) a localised hypoecho lesion
at the marginal liver; (2) the margin between the tumour
and the non-tumour are unclear; (3) the bile duct ecstasies
distal to tumour.32,33 On MRI scanning, T1-weighted mag-
netic resonance imaging revealed a hypointense mass, and
T2-weighted imaging revealed that a central hypointensity
with irregular hyperintense. An important secondary sign
of PHCC was the dilation of the small bile duct distal to
the tumour.34
Treatment and survival
Surgery is the best option for effective and potentially
curative therapy for IHHCC. When diagnosed IHHCC are
large tumours that necessitate major liver resection.21 The
prognosis of cholangiocarcinoma is generally poor with
the presence of lymph node metastases and perineural
infiltration preventing curative surgical resection in most
patients. Several studies demonstrated that lymph node
metastasis of IHHCC was high as 25%, and the lymphatic
drainage was from the hepatoduodenal ligament, hepatic
artery and the back of the head of the pancreas, towards
to the para-aortic lymph nodes. Also in some cases, and
the lymph node metastasis to the greater curvature 
via lesser omentum.23,35 Therefore, the optimal surgical
procedure for PHCC of the left lobe includes removal of
the lesser omentum and lymph node along the gastric
curvature and para-aortic region.
Jan et al analysed the surgical treatment of 373
patients with peripheral cholangiocarcinoma (PCC), they
found the survival rates at 1, 3, and 5 years were 32.5%,
9.2%, and 4.1%, respectively.36 According to a report by
Harrison et al the mean survival period for PHCC was 59
months, the 5-year survival was 42%, and the prognosis
for the patients with vessel invasion and intrahepatic
metastatic nodules was poor.37 Also the 1, 3, and 5-year
survival rates were only 41%, 14%, and 14%, respectively,
according to Yalcin’s report.35 Our result indicated that
the overall cumulative survival rates at 1, 3, and 5 years
were 43.8% (10/23), 13.0% (3/23), and 4.3% (1/23) respec-
tively, and for patients that underwent curative resection
were 88.9% (8/9), 33.3% (3/9), and 11.1% (1/9), respec-
tively, which is significantly longer than those (20.0%,
2/10; 0.0%, 0/10; and 0.0%, 0/10) patients who underwent
palliative resection, respectively (p<0.05). This agrees with
the results reported by Ohtsuka et al, where the 1, 3, and
5-year survival rates were 62%, 38%, and 23% respectively.38
Literature reports and our experience suggest that
cholangiocarcinoma should be suspected in patients 
with any of the following; hepatolithiasis combined with
weight loss, higher levels of serum alkaline phosphatase,
a low level of serum albumin, a serum carcinoembryonic
antigen level exceeding 5.0 ng/mL, detection of a hypere-
choic mass in the liver parenchyma during abdominal
ultrasonography, a nodular tumour mass or an atrophic
and fibrotic liver found during surgery, or hepatolithiasis
that is located either in the right or both lobes of the
liver.37,39
Conclusions
In conclusion, a suspicion of malignancy is necessary in
managing patients with hepatolithiasis. Hepatic resection
with postoperative chemotherapy is the treatment of
choice for cholangiocarcinoma when it is resectable.
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